Delays to Clinical Trials, Treatment and Overseas Expansion Due to the Spread of COVID-19
First written in FY2021. 1 of 3 entries say "Materialised", first in FY2022-Q3. Latest entry: FY2022.
Stella Pharma moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).
The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「Although the COVID-19 pandemic affected our revenue, including through fewer people refraining from cancer screenings and reluctance to travel to medical facilities, we recognise that its impact on our management structure was limited as a result of measures including promoting remote work, restricting business travel and establishing a work-from-home system.」
The disclosure again confirms that the infection affected revenue, while stating that its impact on the management structure was limited by the measures taken. - FY2022-Q3MaterialisedAnnual report
「However, revenue fell below the previous year's level as the impact of the spread of the infection, including a decline in the number of people undergoing cancer screenings and reluctance to travel to medical facilities, coincided with changes in the inventory levels held by pharmaceutical wholesalers.」
The disclosure states that the spread of COVID-19 and other factors led to a decline in cancer screening attendance, restrictions on travel to medical facilities and changes in wholesalers' inventory levels, causing revenue to fall below the previous year's level. - FY2021First statedAnnual report
「If the impact of the COVID-19 pandemic were to become prolonged and more severe, clinical trials, treatment and progress in the development pipeline could be substantially delayed as a result of reduced business activities to prevent infection and expanded restrictions on medical institutions' activities other than routine medical care.」
While describing the impact in the current fiscal year as limited, the disclosure identifies a prolonged and more severe spread of infection as a future risk.